Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 121Breast Neoplasms 81Neoplasms 75Colorectal Neoplasms 65Neoplasm Metastasis 64Leukemia, Myeloid, Acute 62Prostatic Neoplasms 59Recurrence 53Pancreatic Neoplasms 51Ovarian Neoplasms 50Multiple Myeloma 50Triple Negative Breast Neoplasms 36Lung Neoplasms 36Melanoma 35Squamous Cell Carcinoma of Head and Neck 33Lymphoma, Non-Hodgkin 33Glioblastoma 31Carcinoma, Renal Cell 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Lymphoma, Large B-Cell, Diffuse 28Lymphoma 28Endometrial Neoplasms 28Carcinoma, Hepatocellular 28Stomach Neoplasms 26Small Cell Lung Carcinoma 26Leukemia, Lymphocytic, Chronic, B-Cell 26Myelodysplastic Syndromes 24Lymphoma, Follicular 24Lymphoma, B-Cell 24Sarcoma 23

Interventions

ensartinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Advanced Tumor × 90 days × Clear all
NCT07448116 2026-03-04

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

Betta Pharmaceuticals Co., Ltd.

Phase 1/2 Recruiting
164 enrolled

Solid Advanced Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡